Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

jhc

  • Home
  •  
  • jhc



  • Most Read
  • Latest Comments
  • Promising results emerge for HeraMED’s telehealth solution for antenatal care
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Promising results emerge for HeraMED’s telehealth solution for antenatal care
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Promising results emerge for HeraMED’s telehealth solution for antenatal care
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Promising results emerge for HeraMED’s telehealth solution for antenatal care
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Promising results emerge for HeraMED’s telehealth solution for antenatal care
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PainChek locks in performance data for FDA submission, aiming to be  first pain assessment app approved in US
    PainChek locks in performance data for FDA submission, aiming to be first pain assessment app approved in US
    • News

  • HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    • News

  • Promising results emerge for HeraMED’s telehealth solution for antenatal care
    • News

    Promising results emerge for HeraMED’s telehealth solution for antenatal care

    With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers. Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote

    Read More
    Public
  • High-touch, high-quality maternity care could soon become standard in major hospitals
    • News

    High-touch, high-quality maternity care could soon become standard in major hospitals

    Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.